AccuMetab™ Human CYP2C8 Enzyme, Catalytically Active with Cytochrome b5

CAT#: ITS-0426-YL68
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP2C8 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Cytochrome b5 actively facilitates the electron transfer required for CYP2C8 to efficiently metabolize large xenobiotics. Utilizing this high-activity system allows toxicologists to rapidly identify minor clearance pathways and subtle inhibitory interactions that standard assays might miss.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Rapidly processes bulky, large-molecule therapeutics; Identifies minor inhibitory pathways missed in standard assays; Available in multiple reductase ratios
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry